Novan stock plummets as Durham company searches for additional financing


One of the Triangle’s public companies continues to face hardships, as Novan’s stock dives away from the value it needs to stay on the stock exchange.

Previous By the numbers: Precision Biosciences' largest shareholders
Next WellCare addresses concerns, questions about $17.3B Centene acquisition